vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1051Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБА У БОЛЬНОГО ЮНОШЕСКИМ АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ С ПОРАЖЕНИЕМ ГЛАЗEXPERIENCE OF TREATMENT OF JUVENILE ANKYLOSING SPONDYLITIS WITH EYES LESION WITH ADALIMUMABАлексееваЕ.И.AlexeevaE.I.ВалиеваС.И.ValievaS.I.БзароваТ.М.BzarovaT.M.ЛисицинА.О.LisitsinA.O.КарагулянН.А.KaragulyanN.A.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian Federation20092209201581Вопросы современной педиатрии135141Copyright © Алексеева Е., Валиева С., Бзарова Т., Лисицин А., Карагулян Н., 20092009Алексеева Е., Валиева С., Бзарова Т., Лисицин А., Карагулян Н.Alexeeva E., Valieva S., Bzarova T., Lisitsin A., Karagulyan N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1051ReferencesCassidy J., Petty R. Textbook of paediatric rheumatology, 2nd end. New York: Churchill Livigstone. 2002.Cassidy J., Petty R. Textbook of paediatric rheumatology, 2nd end. New York: Churchill Livigstone. 2002.Никишина И.П. Ювенильный анкилозирующий спондилоартрит: клиника и особенности течения. Автореф. дис. ... канд. мед. наук. М. 1995. 20 с.Никишина И.П. Ювенильный анкилозирующий спондилоартрит: клиника и особенности течения. Автореф. дис. ... канд. мед. наук. М. 1995. 20 с.Лисицин А.О., Алексеева Е.И., Бзарова Т.М., и др. Опыт применения адалимумаба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115–120.Лисицин А.О., Алексеева Е.И., Бзарова Т.М., и др. Опыт применения адалимумаба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115–120.Bombardieri S., Ruiz А.А., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF–antagonist therapy in clinical practice. Rheumatology Advance Access. Publ. May 15, 2007. doi:10.1093/rheumatology/kem091.Bombardieri S., Ruiz А.А., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF–antagonist therapy in clinical practice. Rheumatology Advance Access. Publ. May 15, 2007. doi:10.1093/rheumatology/kem091.Nicas S.N., Voulgan P.V., Alamanos Y. et al. Efficacy and safety of switching from Infliximab to adalimumab a comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.Nicas S.N., Voulgan P.V., Alamanos Y. et al. Efficacy and safety of switching from Infliximab to adalimumab a comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.Bennett A.N., Peterson P., Zain A. et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology. 2005; 44: 1026–3101.Bennett A.N., Peterson P., Zain A. et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology. 2005; 44: 1026–3101.Bijl A.E., Breedveld F.C., Antoni C.E. et al. Adalimumab (HUMIRA) is effective in treating patients with rheumatoid arthritis who previously failed infliximab. Ann. Rheum. Dis. 2005; 64 (Suppl. 111): 428.Bijl A.E., Breedveld F.C., Antoni C.E. et al. Adalimumab (HUMIRA) is effective in treating patients with rheumatoid arthritis who previously failed infliximab. Ann. Rheum. Dis. 2005; 64 (Suppl. 111): 428.Wick M.C., Ernestam S., Lmdblad S. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel) results from the STURE registry at Karohnska University Hospital Scand. J. Rheumatol. 2005; 3 (4): 353–358.Wick M.C., Ernestam S., Lmdblad S. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel) results from the STURE registry at Karohnska University Hospital Scand. J. Rheumatol. 2005; 3 (4): 353–358.Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint. Bone Spine. 2004; 71: 601-603.Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint. Bone Spine. 2004; 71: 601-603.Bijl A.E., Breedveld F.C., Antoni C.E. et al. An open label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin. Rheumatol. 2008; 27 (8): 1021–1028.Bijl A.E., Breedveld F.C., Antoni C.E. et al. An open label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin. Rheumatol. 2008; 27 (8): 1021–1028.Haibel H., Rudwaleit M., Listing J. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open label extension up to week fifty two. Arthritis Rheum. 2008; 58 (7): 1981–1991.Haibel H., Rudwaleit M., Listing J. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open label extension up to week fifty two. Arthritis Rheum. 2008; 58 (7): 1981–1991.Dana M.R., Merayo-Lloves J., Schaumberg D.A. et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis–associated uveitis. Ophthalmology. 1997; 104: 236–244.Dana M.R., Merayo-Lloves J., Schaumberg D.A. et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis–associated uveitis. Ophthalmology. 1997; 104: 236–244.Foster C.S. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current Opin Ophthalmol. 2003; 14: 395–398.Foster C.S. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current Opin Ophthalmol. 2003; 14: 395–398.BenEzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89: 444–448.BenEzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89: 444–448.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of Juvenile Idiopathic Arthritis associated Uveitis – A pilot study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0483.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of Juvenile Idiopathic Arthritis associated Uveitis – A pilot study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0483.Vazquez–Cobian L.B., Flynn T., Lehman T.J.A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.Vazquez–Cobian L.B., Flynn T., Lehman T.J.A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.Tynjala P., Kotaniemi K., Lindahl P. et. al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008; 47 (3): 339–344.Tynjala P., Kotaniemi K., Lindahl P. et. al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008; 47 (3): 339–344.Heiligenhaus A., Horneff G., Greiner К. et al. Inhibitors of tumour necrosis factor alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007; 224 (6): 526–531.Heiligenhaus A., Horneff G., Greiner К. et al. Inhibitors of tumour necrosis factor alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007; 224 (6): 526–531.Foeldvari I., Nielsen S., Kummerle-Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis–associated uveitis refractory to second line agents: results of a multinational survey. Nat. Clin. Pract. Rheumatol. 2007; 11: 608–609.Foeldvari I., Nielsen S., Kummerle-Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis–associated uveitis refractory to second line agents: results of a multinational survey. Nat. Clin. Pract. Rheumatol. 2007; 11: 608–609.
The authors declare that there are no conflicts of interest present.